Kedudukan dalam Saham
#35075
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on... Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Harga Saham
$0.594
Disegerakkan terakhir: 2026-08-14
Perubahan (1 tahun)
-66.44%
Perdagangan Mustang Bio, Inc. (MBIO)
Harga MBIO dengan permodalan pasaran b
Modal pasaran bagi Mustang Bio, Inc.(MBIO)
Modal Pasaran: $4.50M
Sehingga August 2026, Mustang Bio, Inc. mempunyai modal pasaran sebanyak $4.50M. Ini menjadikan Mustang Bio, Inc. syarikat ke-35075th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Mustang Bio, Inc. dari 2017 hingga 2026
MBIO berbanding dengan 5 teratas yang paling popular stocks
| Harga MBIO |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.452T
|
+121,120,021.99%
|
|
|
|
|
$4.490T
|
+99,751,364.49%
|
|
|
|
|
$4.162T
|
+92,473,024.90%
|
|
|
|
|
$3.676T
|
+81,674,486.86%
|
|
|
|
|
$2.833T
|
+62,939,517.25%
|
